The safety of switching rapidly from tricyclic antidepressants to monoamine oxidase inhibitors
- PMID: 2738181
The safety of switching rapidly from tricyclic antidepressants to monoamine oxidase inhibitors
Abstract
Monoamine oxidase inhibitors (MAOIs) are increasingly used for patients who do not respond to an initial trial of tricyclic antidepressants (TCAs). Although there are insufficient data documenting the optimal manner for switching a patient from a TCA to an MAOI, standard references advise a drug-free interval of at least 1 week. In clinical practice, however, such a delay may be difficult to observe. In order to explore the safety of a more rapid switch from TCA to MAOI therapy, we survey members of our department (Columbia University) as to their experience with different methods of switching patients from TCAs to MAOIs. Thirty-three respondents reported having switched an estimated 432 patients over the course of 3 years, with 178 patients switched within 4 days of discontinuing TCA therapy, including 63 who had the MAOI added while still being tapered from the TCA. More experienced psychiatrists tended to be less conservative, some using time intervals of 4 days or less. No adverse reactions were reported, including hypertensive and hyperpyrexic crises. This retrospective survey and an accompanying review of the literature suggest that the recommended drug-free interval of a week or more when switching patients from TCAs to MAOIs may be overly conservative.
Similar articles
-
Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression.J Clin Psychiatry. 1985 Jun;46(6):206-9. J Clin Psychiatry. 1985. PMID: 3997787
-
Drug therapy reviews: tricyclic antidepressant and monoamine oxidase inhibitor combination therapy.Am J Hosp Pharm. 1977 Sep;34(9):954-61. Am J Hosp Pharm. 1977. PMID: 333909 Review.
-
[Adverse drug reactions in combined treatment with tricyclic antidepressants and monoamine oxidase inhibitors].Nervenarzt. 1988 Feb;59(2):118-23. Nervenarzt. 1988. PMID: 3362260 German. No abstract available.
-
Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors.J Psychiatry Neurosci. 1997 Mar;22(2):127-31. J Psychiatry Neurosci. 1997. PMID: 9074307 Free PMC article. Review.
-
Tyramine and new monoamine oxidase inhibitor drugs.Br J Psychiatry Suppl. 1989 Oct;(6):32-7. Br J Psychiatry Suppl. 1989. PMID: 2695125 Review.
Cited by
-
The role of monoamine oxidase inhibitors in current psychiatric practice.J Psychiatr Pract. 2004 Jul;10(4):239-48. doi: 10.1097/00131746-200407000-00005. J Psychiatr Pract. 2004. PMID: 15552546 Free PMC article.
-
Moclobemide: therapeutic use and clinical studies.CNS Drug Rev. 2003 Spring;9(1):97-140. doi: 10.1111/j.1527-3458.2003.tb00245.x. CNS Drug Rev. 2003. PMID: 12595913 Free PMC article. Review.
-
Comparative tolerability profiles of the newer versus older antidepressants.Drug Saf. 1994 Jan;10(1):18-46. doi: 10.2165/00002018-199410010-00003. Drug Saf. 1994. PMID: 8136085 Review.
-
Contribution of serotonergic and nitrergic pathways, as well as monoamine oxidase-a and Na+, K+-ATPase enzymes in antidepressant-like action of ((4-tert-butylcyclohexylidene) methyl) (4-methoxystyryl) sulfide (BMMS).Metab Brain Dis. 2019 Oct;34(5):1313-1324. doi: 10.1007/s11011-019-00436-x. Epub 2019 Jun 8. Metab Brain Dis. 2019. PMID: 31177357
-
Monoamine oxidase inhibitory constituents of propolis: kinetics and mechanism of inhibition of recombinant human MAO-A and MAO-B.Molecules. 2014 Nov 18;19(11):18936-52. doi: 10.3390/molecules191118936. Molecules. 2014. PMID: 25412041 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources